Future work could explore designing these killer cell engagers to target multiple NK cell receptors in NSCLC and perhaps cross-linking other cytokines that are known to potentiate NK cell expansion and function, such as IL-2 and IL-18. Here, KLRD1 is linked to non-small cell lung carcinoma.